Trans-Center Small Molecule Screening Laboratory

RCE内的小分子筛选核心的目标是支持与生物防御相关的 旨在开发能够干扰人类健康的新型治疗剂的研究 生物武器的活动。一个完全自动化的设施，能够执行一些小的 分子筛查，将被建立。核心将占据哈佛医学院新改建的空间 学校，它将配备最先进的机器人设备，并将组装一些 合成化合物文库。这些资源，加上训练有素的工作人员的专业知识，将是 向RCE内部的个人调查人员以及有功绩的调查人员提供 新英格兰以外的生物防御相关项目。该核心将与国际教育研究所密切互动 哈佛大学化学和细胞生物学，进一步扩大了核心的能力。基于的专业知识 在核心工作人员的支持下，将支持多种不同的高通量筛查平台，包括 全细菌分析、蛋白质酶分析、蛋白质-蛋白质或蛋白质-配基相互作用分析，以及 利用培养的哺乳动物细胞进行的各种基于细胞的分析。核心将协助调查人员 使用计算机化的数据库对化合物进行后续分析，并将有助于开发更精确的 屏幕。核心的长期目标是促进小说放映的发展 满足不断变化的生物防御需求的平台。此外，它还将作为测试的集中资源 替代天然或合成化合物文库以及促进RCE之间的相互作用 研究人员和药物化学家在开发治疗产品的先导化合物方面。 有前景的化合物的进一步开发将与有兴趣的MAID协商进行评估 工业伙伴，以及NERCE科学指导委员会。

The objective of the Small Molecule Screening Core within the RCE is to support biodefense-related research directed towards the development of new classes of therapeutic agents capable of interfering with the activities of biological weapons. A fully automated facility, capable of executing a number of small molecule screens, will be established. The Core will occupy newly remodeled space at Harvard Medical School, it will be equipped with the state of the art robotic equipment, and will assemble a number of synthetic compound libraries. These resources, together with the expertise of highly trained staff will be made available to individual investigators within the RCE, as well as to investigators with meritorious, biodefense related projects outside of the New England. The core will interact closely with the Institute of Chemistry and Cell Biology at Harvard, further expanding the core's capabilities. Based on the expertise of the Core's staff, a number of diverse, high-throughput screening platforms will be supported, including whole bacterial assays, protein enzyme assays, protein-protein or protein-ligand interaction assays, and a variety of cell-based assays using cultured mammalian cells. The Core will assist the investigators in follow-up analysis of compounds using computerized databases, and will help in the development of moreprecise screens. The long-term objectives of the Core are to promote the development of novel screening platforms to meet changing biodefense needs. Moreover, it will serve as a centralized resource for testing alternative natural or synthetic compound libraries as well as promote interactions between RCE investigators and medicinal chemists in the development of lead compounds to therapeutic products. Further development of promising compounds will be evaluated in consultation with MAID, interested industrial partners, and the NERCE Scientific Steering Committee.